FIELD: medicine.
SUBSTANCE: perftoran is administered intravenously at 5-20 ml per 1 kg of body weight.
EFFECT: reducing side effects in treating methemoglobinemia by the property of perftoran to transform methemoglobin into oxyhemoglobin.
6 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIGITAL DEVICE FOR MONITORING THE PHYSIOLOGICAL HEALTH INDICATORS OF AN AIRCRAFT PILOT | 2021 |
|
RU2766756C1 |
| METHOD FOR DETERMINATION OF HEMOGLOBIN CONCENTRATIONS AND ITS DERIVATIVES IN BLOOD | 2017 |
|
RU2663572C1 |
| METHOD FOR ASSESSING INDUCING ACTION OF AGGRAVATED CYTOMEGALOVIRUS INFECTION IN PREGNANT WOMAN IN THIRD TRIMESTER OF GESTATION ON METHAEMOGLOBIN AND HAEMOGLOBIN OXYGENATION IN NEWBORN'S PERIPHERAL BLOOD | 2013 |
|
RU2536235C1 |
| METHOD OF DETERMINING HEMOGLOBIN CONCENTRATION IN BIOLOGICAL TISSUES | 2012 |
|
RU2501522C2 |
| POLYFUNCTIONAL POLYHEMOGLOBIN-ENZYME COMPLEX | 2010 |
|
RU2432172C1 |
| METHOD FOR DETERMINING HAEMOGLOBIN DERIVATIVE CONCENTRATIONS IN BIOLOGICAL TISSUES | 2013 |
|
RU2517155C1 |
| DONOR OF NITROGEN OXIDE ACTIVATING SOLUBLE FORM OF GUANYLATE CYCLASE, INHIBITING PLATELET AGGREGATION AND EXHIBITING SPASMOLYTIC AND VASODILATING EFFECT | 2001 |
|
RU2208438C1 |
| METHOD OF DETERMINATION OF CONTENT OF MAIN DERIVATIVES OF HEMOGLOBIN | 1998 |
|
RU2140083C1 |
| HAEMOGLOBIN COMPOSITION | 2010 |
|
RU2589254C2 |
| EARLY STAGE DIAGNOSIS METHOD FOR DIAGNOSING MICRO-ANGIOPATHY CASES IN I TYPE DIABETES MELLITUS PATIENTS | 2005 |
|
RU2316004C2 |
